Recently, Profil Institute for Clinical Research, a science-driven clinical research organization (CRO), and mySugr, a diabetes mobile app developer, announced a partnership to “design and conduct a clinical research and development program for mySugr’s portfolio of diabetes mobile health applications.”
According to a media announcement, under the terms of the agreement, the companies plan to jointly “design and execute a development program aimed at enhancing and validating the clinical and health economic impact of mySugr’s digital health solutions for diabetes management.”
As part of a multi-year plan, the companies plan to generate, analyze and publish data from prospective and retrospective studies to increase evidence-based research in the field of mobile health app development.
“Patients already understand the positive impact of mySugr’s digital health solutions on their diabetes therapy. However, digital diabetes therapy still lacks a clear clinical interpretation of the vast amount of data generated. We need to better understand the exact impact of digital tools by examining evidence-based outcomes to determine where we can add even more value to diabetes therapy,” said Frank Westermann, CEO of mySugr.
“mHealth and telemedicine have the potential to improve the quality of clinical care across a wide range of chronic disorders. This is particularly true for diabetes, where patients themselves are often required to collect, integrate, analyze, share and respond to a wide range of personal health data,” said Dr. Marcus Hompesch, Chairman and CEO of Profil Institute.